company background image
SWAV

ShockWave Medical NasdaqGS:SWAV Stock Report

Last Price

US$278.07

Market Cap

US$10.0b

7D

10.3%

1Y

39.3%

Updated

30 Sep, 2022

Data

Company Financials +
SWAV fundamental analysis
Snowflake Score
Valuation0/6
Future Growth6/6
Past Performance3/6
Financial Health5/6
Dividends0/6

SWAV Stock Overview

ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide.

ShockWave Medical, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ShockWave Medical
Historical stock prices
Current Share PriceUS$278.07
52 Week HighUS$314.90
52 Week LowUS$113.36
Beta1.06
1 Month Change-6.33%
3 Month Change40.00%
1 Year Change39.34%
3 Year Change763.04%
5 Year Changen/a
Change since IPO811.71%

Recent News & Updates

Sep 25
ShockWave Medical (NASDAQ:SWAV) Shareholders Will Want The ROCE Trajectory To Continue

ShockWave Medical (NASDAQ:SWAV) Shareholders Will Want The ROCE Trajectory To Continue

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...

Sep 19

Shockwave Medical initiates all-female coronary IVL study

Shockwave Medical (NASDAQ:SWAV) said it had begun the prospective coronary intervention study consisting of all female patients to determine whether the positive results from earlier coronary Intravascular Lithotripsy (IVL) studies with its Shockwave C2 Coronary IVL Catheter, which showed similar safety outcomes across both sexes, can be replicated in the population of female patients with severely calcified coronary lesions. This study will enroll up to 400 female patients with symptomatic ischemic heart disease in up to 50 investigational centers in the United States and Europe and will include a 3-year follow-up. "Despite often being more challenging to treat, female patients are under-represented in published data, and there have been no dedicated prospective studies performed on this population. EMPOWER CAD will be an extremely valuable study to better inform interventional cardiologists on the optimal treatment strategy for these complex patients," the company said.

Sep 06

ShockWave Medical falls as Oppenheimer downgrades

Medical device maker ShockWave Medical (NASDAQ:SWAV) lost ~5% in the morning hours Tuesday after Oppenheimer downgraded its shares to Underperform from Perform, citing overly optimistic expectations on the company’s quarterly results. With a $165 per share target, the analyst Suraj Kalia wrote: “Quarterly outperformance cannot keep up with expectations, in our view.” Santa Clara, California-based SWAV offers a range of catheters to treat arterial diseases, and the company has beaten Street forecasts for both revenue and earnings for three consecutive quarters. Meanwhile, SWAV’s “IP moat has been completely dismantled by Cardiovascular Systems,” Kalia added, referring to a rival maker of peripheral artery disease products. “Wall Street has remained bullish on ShockWave Medical (SWAV) stock, with an average rating of Buy from analysts. However, Seeking Alpha contributor ratings as well as our quant system, which consistently beats the market, rates SWAV as a Hold.

Shareholder Returns

SWAVUS Medical EquipmentUS Market
7D10.3%-1.8%-2.5%
1Y39.3%-31.2%-23.2%

Return vs Industry: SWAV exceeded the US Medical Equipment industry which returned -29.9% over the past year.

Return vs Market: SWAV exceeded the US Market which returned -21.5% over the past year.

Price Volatility

Is SWAV's price volatile compared to industry and market?
SWAV volatility
SWAV Average Weekly Movement7.8%
Medical Equipment Industry Average Movement8.5%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: SWAV is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: SWAV's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009657Doug Godshallhttps://www.shockwavemedical.com

ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors.

ShockWave Medical, Inc. Fundamentals Summary

How do ShockWave Medical's earnings and revenue compare to its market cap?
SWAV fundamental statistics
Market CapUS$9.99b
Earnings (TTM)US$54.97m
Revenue (TTM)US$363.72m

181.7x

P/E Ratio

27.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SWAV income statement (TTM)
RevenueUS$363.72m
Cost of RevenueUS$53.23m
Gross ProfitUS$310.48m
Other ExpensesUS$255.51m
EarningsUS$54.97m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 07, 2022

Earnings per share (EPS)1.53
Gross Margin85.36%
Net Profit Margin15.11%
Debt/Equity Ratio5.7%

How did SWAV perform over the long term?

See historical performance and comparison